Robert A Ritzel

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/199447/publications.pdf

Version: 2024-02-01

14 papers

4,545 citations

759233 12 h-index 14 g-index

15 all docs

15 docs citations

15 times ranked 5079 citing authors

#	Article	IF	CITATIONS
1	Similar glycaemic control and less hypoglycaemia during active titration after insulin initiation with glargine 300 units/mL and degludec 100 units/mL: A subanalysis of the BRIGHT study. Diabetes, Obesity and Metabolism, 2020, 22, 346-354.	4.4	6
2	Better glycaemic control and less hypoglycaemia with insulin glargine 300 <scp>U/mL</scp> vs glargine 100 <scp>U/mL</scp> : 1â€year patientâ€level metaâ€analysis of the <scp>EDITION</scp> clinical studies in people with type 2 diabetes. Diabetes, Obesity and Metabolism, 2018, 20, 541-548.	4.4	69
3	Glycaemic control and hypoglycaemia benefits with insulin glargine 300 U/mL extend to people with type 2 diabetes and mildâ€toâ€moderate renal impairment. Diabetes, Obesity and Metabolism, 2018, 20, 2860-2868.	4.4	20
4	More Similarities Than Differences Testing Insulin Glargine 300 Units/mL Versus Insulin Degludec 100 Units/mL in Insulin-Naive Type 2 Diabetes: The Randomized Head-to-Head BRIGHT Trial. Diabetes Care, 2018, 41, 2147-2154.	8.6	159
5	A Randomized Controlled Trial Comparing Efficacy and Safety of Insulin Glargine 300 Units/mL Versus 100 Units/mL in Older People With Type 2 Diabetes: Results From the SENIOR Study. Diabetes Care, 2018, 41, 1672-1680.	8.6	44
6	Beta-cell selective KATP-channel activation protects beta-cells and human islets from human islet amyloid polypeptide induced toxicity. Regulatory Peptides, 2010, 165, 158-162.	1.9	10
7	Therapeutic approaches based on beta-cell mass preservation and/or regeneration. Frontiers in Bioscience - Landmark, 2009, Volume, 1835.	3.0	17
8	Annexin A5 Directly Interacts with Amyloidogenic Proteins and Reduces Their Toxicity. Biochemistry, 2009, 48, 10568-10576.	2.5	19
9	Human Islet Amyloid Polypeptide Oligomers Disrupt Cell Coupling, Induce Apoptosis, and Impair Insulin Secretion in Isolated Human Islets. Diabetes, 2007, 56, 65-71.	0.6	170
10	Relationship Between Â-Cell Mass and Fasting Blood Glucose Concentration in Humans. Diabetes Care, 2006, 29, 717-718.	8.6	184
11	Induction of \hat{l}^2 -Cell Rest by a Kir6.2/SUR1-Selective KATP-Channel Opener Preserves \hat{l}^2 -Cell Insulin Stores and Insulin Secretion in Human Islets Cultured at High (11 mM) Glucose. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 795-805.	3.6	72
12	Î ² -Cell Deficit and Increased Î ² -Cell Apoptosis in Humans With Type 2 Diabetes. Diabetes, 2003, 52, 102-110.	0.6	3,615
13	Replication Increases Â-Cell Vulnerability to Human Islet Amyloid Polypeptide-Induced Apoptosis. Diabetes, 2003, 52, 1701-1708.	0.6	107
14	Glucose Stimulates Pulsatile Insulin Secretion from Human Pancreatic Islets by Increasing Secretory Burst Mass: Dose-Response Relationships. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 742-747.	3.6	53